SynthesisReviews in cardiovascular medicine2024
Quality of Life and Safety Outcomes after First-Line Treatment of Symptomatic AF with Cryoablation or Drug Therapy: A Meta-Analysis of Randomized Controlled Trials.
Synthesis in Reviews in cardiovascular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-analysis of perioperative amiodarone for prevention of postoperative atrial fibrillation (POAF) in cardiac surgery patients: update and reevaluation of timing, route, and dosage.BMC cardiovascular disorders · 2026Pooled it
- Perivascular fat attenuation index on coronary computed tomography angiography predicts postoperative atrial fibrillation after off-pump coronary artery bypass grafting.BMC cardiovascular disorders · 2026Article
- Associations of chronic pain and genetic risks with incident atrial fibrillation: a prospective cohort study.BMC cardiovascular disorders · 2026Article
- A model for prediction of recurrence risk after zero-fluoroscopy catheter ablation for patients with paroxysmal atrial fibrillation.BMC research notes · 2026Article
- High-density mapping guided the modified box and driver ablation for non-paroxysmal atrial fibrillation: a retrospective single-center study.BMC cardiovascular disorders · 2026Article
- Mediating role of self-efficacy for appropriate medication use in the relationship between medication literacy and medication adherence among patients with atrial fibrillation: a longitudinal study.BMC cardiovascular disorders · 2026Article
- Heart-rate-derived variability measures and in-hospital mortality in critically ill patients with heart failure and atrial fibrillation: insights from the MIMIC-IV database.BMC cardiovascular disorders · 2026Article
- A case of transient tachy-bradycardia syndrome following combined atrial fibrillation ablation and left atrial appendage closure.BMC cardiovascular disorders · 2026Article
- Development and validation of a nomogram model based on inflammatory markers and cardiac parameters: predicting the risk of recurrence in patients with atrial fibrillation after radiofrequency catheter ablation.BMC cardiovascular disorders · 2026Article
- The interactive effect of sex and neutrophil-to-lymphocyte ratio on short-term poor outcomes in patients with nonvalvular atrial fibrillation-related acute cardioembolic stroke.European journal of medical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cryoablation has emerged as a recognized interventional strategy for the treatment of atrial fibrillation (AF). Numerous trials have investigated cryoablation as a first-line therapy for AF. This meta-analysis aimed to evaluate the impact of cryoablation on quality of life (QoL) and safety outcomes compared to antiarrhythmic drugs (AADs) in patients with symptomatic AF. Methods: A comprehensive search of the PubMed, EMBASE, and Cochrane Library databases was conducted for randomized controlled trials (RCTs) comparing cryoablation and AADs as first-line treatments for AF until May 2023. Continuous outcome data were analyzed using mean differences (MDs) with 95% confidence intervals (CIs), and dichotomous outcome data were analyzed using relative risks (RRs) with 95% CIs. The primary outcomes assessed were QoL and serious adverse events. Results: Our analysis included four RCTs involving 928 patients. Cryoablation was associated with a significant improvement in the AF Effect on Quality of Life (AFEQT) score (3 trials; MD 7.46, 95% CI 2.50 to 12.42; Conclusions: Cryoablation, as a first-line treatment for symptomatic AF patients, significantly improved AF-specific quality of life and reduced serious adverse events, as well as overall adverse events, persistent AF, hospitalizations, and additional ablation compared to AADs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.